1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. MediPharm Labs Corp.
  6. Summary
    LABS   CA58504D1006

MEDIPHARM LABS CORP.

(LABS)
  Report
Delayed Quote. Delayed Toronto Stock Exchange - 05/16 03:59:59 pm
0.09 CAD   +12.50%
05/16TRANSCRIPT : MediPharm Labs Corp., Q1 2022 Earnings Call, May 16, 2022
CI
05/16MediPharm Labs Posts Q1 Net loss Near $7.5 Million
MT
05/16MediPharm Labs Reports First Quarter Results
PR
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Toronto Stock Exchange
05/10/2022 05/11/2022 05/12/2022 05/13/2022 05/16/2022 Date
0.095(c) 0.095(c) 0.09(c) 0.08(c) 0.09(c) Last
1 008 835 349 348 1 535 645 2 962 107 1 088 358 Volume
-9.52% 0.00% -5.26% -11.11% +12.50% Change
More quotes
Estimated financial data (e)
Sales 2022 33,3 M 25,8 M 25,8 M
Net income 2022 -23,0 M -17,8 M -17,8 M
Net Debt 2022 - - -
P/E ratio 2022 -1,17x
Yield 2022 -
Sales 2023 43,9 M 34,0 M 34,0 M
Net income 2023 -17,1 M -13,3 M -13,3 M
Net Debt 2023 - - -
P/E ratio 2023 -1,80x
Yield 2023 -
Capitalization 24,7 M 19,1 M 19,1 M
Capi. / Sales 2022 0,74x
Capi. / Sales 2023 0,56x
Nbr of Employees 190
Free-Float 93,7%
More Financials
Company
MediPharm Labs Corp. is a Canada-based pharmaceutical company that is specialized in cannabis. The Company produces purified, pharmaceutical-like cannabis extracts and related derivative products. The Company formulates, processes, packages and distributes cannabis extracts and cannabinoid-based products at its Canadian and Australian facilities for domestic and international markets. The Company, through its... 
Sector
Pharmaceuticals
Calendar
06/30Shareholder meeting
More about the company
Ratings of MediPharm Labs Corp.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D
More Ratings
All news about MEDIPHARM LABS CORP.
05/16TRANSCRIPT : MediPharm Labs Corp., Q1 2022 Earnings Call, May 16, 2022
CI
05/16MediPharm Labs Posts Q1 Net loss Near $7.5 Million
MT
05/16MediPharm Labs Reports First Quarter Results
PR
05/16NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
05/13NORTH AMERICAN MORNING BRIEFING : Tech Futures -2-
DJ
05/12MediPharm Labs Sets Date to Report First Quarter 2022 Financial Results
AQ
04/20MediPharm Labs Names Experienced Pharma and Med Tech Executive David Pidduck, as CEO
PR
04/20MediPharm Labs Corp. Announces CEO Changes
CI
04/20MediPharm Labs Corp. Announces Management Changes
CI
04/08Most actively traded companies on the Toronto Stock Exchange
AQ
04/06MediPharm Labs Continues to Lead with Innovation, Launches CBG and Water-Soluble Produc..
AQ
04/05MediPharm Labs Continues to Lead with Innovation - Launches CBG and Water-Soluble Produ..
AQ
04/05Medipharm Labs Corp Launches CBG and Water-Soluble Products
CI
04/01TRANSCRIPT : MediPharm Labs Corp., Q4 2021 Earnings Call, Apr 01, 2022
CI
03/31MEDIPHARM LABS BRIEF : Warren Everitt and MediPharm Labs Have Mutually Agreed to End the R..
MT
More news
News in other languages on MEDIPHARM LABS CORP.
05/16MediPharm Labs affiche une perte nette de près de 7,5 millions de dollars au premier tr..
04/20MediPharm Labs Corp. annonce des changements de PDG
04/20MediPharm Labs Corp. annonce des changements de direction
04/05Medipharm Labs Corp lance des produits CBG et hydrosolubles
03/31MediPharm Labs Corp. annonce ses résultats pour l'année complète se terminant le 31 déc..
More news
Chart MEDIPHARM LABS CORP.
Duration : Period :
MediPharm Labs Corp. Technical Analysis Chart | LABS | CA58504D1006 | MarketScreener
Technical analysis trends MEDIPHARM LABS CORP.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Last Close Price 0,09 CAD
Average target price 0,25 CAD
Spread / Average Target 178%
EPS Revisions
Managers and Directors
David A. Pidduck Chief Executive Officer & Director
Keith Strachan President
Greg Hunter Chief Financial Officer
Chris Taves Chairman
Ina Shira Dubinsky Lead Scientist-Secondary Processing